Health committee  It's to move away from sole-source procurement strategies. Find a way to have multiple sources of supply, in which you can adjust and gear up when things happen.

Health committee  I think that's it. Right now we believe that if you do sole-source contracting, you're driving away competition, you're driving away choice, and you won't be able to adjust later on, notwithstanding the great efforts we're going to do in terms of reporting.

Health committee  I think the individual buyers. As you see, HealthPRO is talking about it. I think the provinces and the federal government—

Health committee  In terms of purchasing?

Health committee  It's the marketplace that will control that. So if the private sector is buying, they will control it. If governments are buying it, they should control it.

Health committee  The government. For instance, if it's a government program—

Health committee  Thank you very much. I may have to meet you after this meeting in order to answer all of your questions. The cost of medication...

Health committee  You have given me quite a challenge, but thank you all the same. The PMPRB, the national body that monitors the price of medicine, has shown that the price of brand name drugs has decreased over the past two years whereas the cost of generics has gone up, and this is because of

Health committee  I can at least begin. Thank you for asking this very complex question. You are quite right in saying that the solution...

Health committee  Thank you. With respect to your question about diversifying sources of supply, this morning I heard that HealthPRO was going to make a suggestion. Perhaps this may be a model that we could use. At the federal level, we have worked on the vaccination file in the past. That may of

Health committee  Merci beaucoup. Thank you, Madam Chair. Thank you, committee members, for the opportunity to appear before you today. As you mentioned, seated with me is Mark Ferdinand, our senior director of health and economic policy. He has been a key worker in terms of the working group

International Trade committee  It's based on the fundamentally flawed premise that weak IP can be used to control health costs. A number of studies have shown that a lot of what they talk about has not come true. During the last 20 years, in the 1980s and in 2006, when the government has moved forward on data

International Trade committee  We've seen it being whittled away. It's a quiet death by a thousand cuts. Other research areas are getting it. We spend about $100 billion a year on research around the world. Every jurisdiction is absolutely doing its best to try to get it. When we try to win those contracts, we

International Trade committee  We haven't seen it. What we are seeing is that as we are talking about creating a free trade environment, this is a golden opportunity for Canada to be in a privileged position to do that research that will save lives and improve our health care system. Here's an opportunity, wit

International Trade committee  I will ask Declan to comment. We are saying there are a lot of discussions that aren't comparing apples with apples. There is a lot of misinformation. In fact, Norton Rose has just done an analysis, which we can table. There were 22 products studied, and for well over the majorit